Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

Clinical trial NCT05209620 · RECRUITING

Trial details

NCT number: NCT05209620
Sponsor: Henan Cancer Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Central Nervous System Lymphoma

Start date: 2021-12-21
Primary completion: 2025-06-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.